FOLFIRI
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
FOLFIRI
Apr 12, 2024, 12:10 |
Insight
Piotr Wysocki: Cetuximab monotherapy maintenance after FOLFIRI may not be the optimal choice but can be considered in selected mCRC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 6, 2024, 16:25 |
Insight
New Article Alert! FOLFIRI plus durvalumab with or without tremelimumab in advanced gastric or GEJ adenocarcinoma
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal…
All:
2
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube